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declines until a steady state is reached where HBV
transmission is maintained at low endemic levels. On the
basis of this model of HBV transmission, vaccination of age
cohorts with an increasing prevalence of HBV markers could
contribute substantially to interrupting HBV transmission by
decreasing the number of susceptibles (members of the
popula ion with no HBV markers). Hence, vaccination
wastage may not be an important factor mitigating against
vaccination of children in the first decade of life.
Which is the best vaccination
option for South Africa?
Given the high levels of HBV transmission in childhood,
particularly during the preschool and primary school years, it
is important to have the cohort of children from birth to 10
years protected as soon as possible. Option 3 is my
proposed option. It is unfortunate that this decision was not
made in 1994/95 so that the dual vaccination age could
have been implemented right at the start of the HBV
vaccination programme. Even though HBV vaccination is in
its 3rd year, the introduction in 1998 of routine HBV
vaccination at both birth and 5 years would substantially
speed up HBV protection in childhood. This approach would
mean that by the year 2000, the cohort of birth to 7 years
will be vaccinated. This catch-up vaccination at 5 years
would need to be implemented for 3 years only, from 1998
to 2000. Thereafter, only the routine newborn vaccination
need continue.
Why select 5 years for the catch-
up vaccination?
HBV transmission is still well below its peak at 5 years.
There are high levels of susceptibles at 5 years. The routine
EPI of the South African health service includes a
vaccination visit at 5 years for 01. Including the first dose of
HBV vaccine at this visit will minimise the effort involved in
informing mothers to bring their children for HBV vaccination
at 5 years. During vaccination with the first dose,
appointments for the follow-up doses can be provided
together with counselling on the importance of not missing
them. A further point is that HBV vaccination coverage in 5-
year-old children can be monitored at 6 years when the
children enter school.
In conclusion, data on the age-specific prevalence of HBV
infection suggest that a dual-age HBV vaccination strategy
is a better option than the current strategy of infant
vaccination. HBV control is within our grasp in South Africa;
using a dual-age strategy will mean that we can realise this
goal sooner rather than later.
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The conventional treatment for patients with an acute deep-
vein thrombosis (DVT) at present consists of an initial
continuous intravenous infusion of unfractionated heparin,
administered for a minimum of 5 - 7 days.' Oral
anticoagulation is started at the same time, while the patient
is still in hospital, and is continued for at least 3 months. The
initial treatment with heparin, which aims to prevent
pulmonary embolism and recurrent thrombosis, has been
found to be effective! but the anticoagulant response to
unfractionated heparin varies markedly. As a consequence
the dosage of unfractionated heparin must be monitored
carefUlly by frequent measurement of activated partial
thromboplastin times (aPTIs), necessitating hospitalisation
of the patient for the period that the unfractionated heparin
is being administered.
Low-molecular-weight heparins (LMWHs), prepared from
digestion of heparin by chemical or enzymatic
depolymerisation (to produce molecules that are usually less
than 18 saccharide units in length), have several advantages
over the parent compound.
1. The anticoagulant activity of the heparins resides in a
unique pentasaccharide sequence which is randomly
distributed along the heparin chains and binds with high
affinity to antithrombin. Any heparin (no matter how long the
molecule), containing this pentasaccharide sequence,
inactivates factor Xa simply by binding to antithrombin and
thereby accelerating the interaction between factor Xa and
antithrombin. In contrast, the inactivation of thrombin by
unfractionated heparin requires heparin to bind to both
antithrombin and thrombin. This complex can only be
formed if the heparin chains are at least 18 saccharide units
long and also include the pentasaccharide sequence (most
molecules of unfractionated heparin are at least 18
saccharide units in length). As a result, unfractionated
heparin has equivalent inhibitory activity against both factor
Xa and thrombin, while LMWHs preferentially inactivate
factor Xa.
2. Unlike unfractionated heparin, LMWHs can inactivate
platelet-bound factor Xa and can resist inhibition by platelet
factor 4, which is released during clotting.
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3. LMWHs may also cause fewer haemorrhagic
complications as a result of their less pronounced effect on
platelet and vascular endothelial function.
These characteristics result in a longer half-life, better bio-
availability, and more predictable anticoagulant activity.3.'
The LMWHs can therefore be administered subcutaneously,
without laboratory monitoring, in a dosage determined by
the patient's weight alone.
Initially, LMWHs were used in small doses in the
prevention of venous thrombosis in high-risk patients' In
this setting they are as effective at preventing the
development of DVTs as low-dose subcutaneous
unfractionated heparin (Kakkar's regimen), if not more so. In
addition, bleeding complications appear to be reduced and
the drug can generally be administered as a single daily
dose when used for this indication.
Subsequently, a number of excellent randomised studies
have demonstrated that weight-adjusted fixed-dose LMWH
given subcutaneously is as effective as intravenous
unfractionated heparin (dose-adjusted to prolong the aPTT)
in the initial treatment of hospitalised patients with DVT.~14
These studies have recently been summarised in a meta-
analysis.'s
1. The venographically determined thrombus size (5th to
10th day after treatment was started) was reduced in 64%
of patients receiving LMWH compared with 50% in those
receiving unfractionated heparin (P < 0.001.) Similarly, there
was an increase in thrombus size in 6% of patients receiving
LMWH compared with 12% in those receiving
unfractionated heparin (P < 0.001).
2. The incidence of major bleeding was 3.2% in the
patients receiving unfractionated heparin compared with
0.9% in those receiving LMWH (risk reduction 68%;
P < 0.005).
3. The recurrence rate of clinically apparent DVT was
lower in those patients receiving LMWH (unfractionated
heparin 7% v. LMWH = 2.7%; risk reduction 61 %;
P < 0.005), as was mortality (unfractionated heparin 8.1 % v.
LMWH 4.3%; risk reduction 48%; P < 0.03).
As a result of these studies, many centres (particularly in
Europe) have used LMWH in an outpatient setting as the
initial form of therapy in selected patients presenting with
DVT. That this is effective and safe has been shown in two
recently published studies.'·17 In both these studies
unfractionated heparin given intravenously to hospitalised
patients was compared with LMWH given subcutaneously to
patients at home. The use of LMWH in an outpatient setting
for the treatment of DVT not only increases patient
convenience but also reduces hospital costs dramatically.
The major concern regarding the use of LMWHs in an
outpatient setting is the possible complications. The two
studies mentioned above revealed that life-threatening
pulmonary embolism was exceedingly rare with both
modalities of treatment, and when death did occur it was
not clear that the outcome would have been improved if the
patients had been treated in hospital. On the other hand,
bleeding complications are potentially more treatable in
hospital. It is therefore prudent to treat patients with a
coexisting risk of bleeding in a hospital environment,
irrespective of the type of heparin used.
In conclusion, LMWHs given in a fixed dose without
laboratory monitoring are at least as effective as carefully
monitored standard unfractionated heparin administered by
continuous intravenous infusion. As they produce less
bleeding for eqUivalent antithrombotic effects, their use in
outpatient treatment of DVT has been studied and been
found to be safe in selected patients. The resultant increase
in patient convenience and reduction in hospitalisation make
this a very attractive alternative to the standard form of initial
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